Table 1.
Literature overview for the management of graft versus host disease with WJ-MSCs infusions
| Authors | No. of patients | Disease | Grade GvHD | Nr. of WJ-MSCs infusions | Dose of WJ-MSCs infused (×106 cells per kg body weight) | Side effect during or after WJ-MSCs infusions | Clinical outcome |
|---|---|---|---|---|---|---|---|
| Kang-Hsi Wu et al. | 1 | 1 aGvHD | IV | 3 | 3.3 (at passage 3), 7.2 (at passage 3), 8.0 (at passage 4) | None | CR |
| 1 | 1 aGvHD | IV | 1 | 4.1 (at passage 3) | None | CR | |
| Boruczkowsi et al. | 10 | 7 aGvHD | 6 IV, 1 III | 1~3 | 1.5 median dose (range 1.1~4.9) | None | 2 CR, 2 PR, 3 NR |
| 3 cGvHD | 3 extensive | 2 PR, 1 NR | |||||
| Qiu-Ling Wu et al. | 24 | 8 aGvHD | 2 II, 4III, 2 IV | 1 | 0.6 median dose (range 0.5~1.0) | None | 6 OR, 2 NR |
| 16 cGvHD | 12 extensive, 4 localized | 14 OR, 2 NR |
WJ-MSCs: Wharton’s jelly mesenchymal stem cells, aGvHD: acute Graft Versus Host Disease, cGvHD: crhonic Graft Versus Host Disease, NR: no response, CR: complete response, PR: partial response, OR: overall response (complete+partial response).